News | October 22, 2025
RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Expanding US operations to address the increased demand for API development and manufacturing
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Subscribe To Our Newsletter & Stay Updated
